查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968149

全球個人化醫療生物標記市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Personalized Medicine Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 174 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計個人化醫療生物標記市場將從 2025 年的 266.4 億美元成長到 2034 年的 982.7 億美元，2026 年至 2034 年的複合年成長率為 15.61%。

受對標靶性、患者特異性治療方法的需求不斷成長的推動，全球個人化醫療生物標記市場正經歷穩步成長。生物標記在識別疾病模式、預測治療反應和提高診斷準確性方面發揮著至關重要的作用。隨著醫療保健系統向精準醫療轉型，生物標記在個人化療法開發中的重要性日益凸顯。

基因組學的進步、慢性病病例的增加以及研發投入的加大是推動市場成長的主要因素。製藥公司正致力於基於生物標記的藥物研發，以提高治療成功率並減少副作用。此外，政府的支持措施和診斷技術的進步也促進了市場擴張。

未來，分子診斷和人工智慧（AI）領域的創新預計將對市場產生積極影響。隨著越來越多的臨床試驗採用生物標記主導的方法，對可靠且先進的檢測解決方案的需求將會增加。個人化醫療的發展趨勢將進一步強化生物標記在現代醫學中的作用，從而確保市場的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球個人化醫療生物標記市場：依生物標記類型分類

  • 市場分析、洞察與預測
  • 基因組
  • 蛋白質體學
  • 代謝
  • 其他類型的生物標記

第5章 全球個人化醫療生物標記市場：按應用分類

  • 市場分析、洞察與預測
  • 早期檢測和篩檢
  • 診斷
  • 治療方案
  • 監測
  • 其他用途

第6章 全球個人化醫療生物標記市場：依適應症分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 神經病學
  • 糖尿病
  • 自體免疫疾病
  • 心臟病學
  • 其他跡象

第7章 全球個人化醫療生物標記市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院和診所
  • 製藥和生物技術公司
  • 診斷檢測實驗室
  • 其他最終用戶

第8章 全球個人化醫療生物標記市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott Laboratories
    • Bio-Rad Laboratories
    • Danaher
    • EKF Diagnostics Holdings
    • F. Hoffmann-La Roche
    • Illumina
    • Lifesign
    • Merck
    • Myriad Genetics
    • Qiagen
    • Signosis
    • Singulex
    • Thermo Fisher Scientific
簡介目錄
Product Code: VMR112110341

The Personalized Medicine Biomarkers Market size is expected to reach USD 98.27 Billion in 2034 from USD 26.64 Billion (2025) growing at a CAGR of 15.61% during 2026-2034.

The Global Personalized Medicine Biomarkers Market is experiencing steady growth due to the increasing demand for targeted and patient-specific treatments. Biomarkers play a crucial role in identifying disease patterns, predicting treatment responses, and improving diagnostic accuracy. As healthcare systems move toward precision medicine, the importance of biomarkers in developing personalized therapies is rising significantly.

Growth is mainly driven by advancements in genomics, rising cases of chronic diseases, and increasing investments in research and development. Pharmaceutical companies are focusing on biomarker-based drug development to enhance treatment success rates and reduce side effects. Additionally, supportive government initiatives and improved diagnostic technologies are contributing to market expansion.

In the future, the market is expected to benefit from innovations in molecular diagnostics and artificial intelligence. As more clinical trials adopt biomarker-driven approaches, the demand for reliable and advanced testing solutions will grow. Personalized healthcare trends will continue to strengthen the role of biomarkers in modern medicine, ensuring long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Biomarker Type

  • Genomic
  • Proteomics
  • Metabolic
  • Other Biomarker Types

By Application

  • Early Detection/Screening
  • Diagnosis
  • Treatment Selection
  • Monitoring
  • Other Applications

By Disease Indication

  • Oncology
  • Neurology
  • Diabetes
  • Autoimmune Diseases
  • Cardiology
  • Other Indications

By End Use

  • Hospitals and Clinics
  • Pharmaceutical and Biotechnology Companies
  • Diagnostic Labs
  • Other End Users

COMPANIES PROFILED

  • Abbott Laboratories, BioRad Laboratories, Danaher, EKF Diagnostics Holdings, F HoffmannLa Roche, Illumina, Lifesign, Merck, Myriad Genetics, Qiagen, Signosis, Singulex, Thermo Fisher Scientific
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY BIOMARKER TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Biomarker Type
  • 4.2. Genomic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Proteomics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Metabolic Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Other Biomarker Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Early Detection/Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Treatment Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Disease Indication
  • 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY END USE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End Use
  • 7.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Pharmaceutical and Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Diagnostic Labs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PERSONALIZED MEDICINE BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Biomarker Type
    • 8.2.2 By Application
    • 8.2.3 By Disease Indication
    • 8.2.4 By End Use
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Biomarker Type
    • 8.3.2 By Application
    • 8.3.3 By Disease Indication
    • 8.3.4 By End Use
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Biomarker Type
    • 8.4.2 By Application
    • 8.4.3 By Disease Indication
    • 8.4.4 By End Use
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Biomarker Type
    • 8.5.2 By Application
    • 8.5.3 By Disease Indication
    • 8.5.4 By End Use
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Biomarker Type
    • 8.6.2 By Application
    • 8.6.3 By Disease Indication
    • 8.6.4 By End Use
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PERSONALIZED MEDICINE BIOMARKERS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Abbott Laboratories
    • 10.2.2 Bio-Rad Laboratories
    • 10.2.3 Danaher
    • 10.2.4 EKF Diagnostics Holdings
    • 10.2.5 F. Hoffmann-La Roche
    • 10.2.6 Illumina
    • 10.2.7 Lifesign
    • 10.2.8 Merck
    • 10.2.9 Myriad Genetics
    • 10.2.10 Qiagen
    • 10.2.11 Signosis
    • 10.2.12 Singulex
    • 10.2.13 Thermo Fisher Scientific